The current clinically used biomarkers such as alpha-fetoprotein (AFP) fail to meet the needs for accurate prognosis and treatment stratification of HCC because of low sensitivity and specificity6, 7. The gene discussed is AFP; the disease is hepatocellular carcinoma.